May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Reflects on "Incredible" Data Seen With bb2121 in Heavily Pretreated Myeloma
August 29th 2018Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma, including the promising results seen with the anti-BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory disease.
Read More
Once-Weekly Carfilzomib Submitted for FDA Approval in Myeloma
August 27th 2018FDA approval is being sought for a once-weekly dosing option of carfilzomib for use in combination with dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma. Amgen, the manufacturer of the proteasome inhibitor, announced the submission of a supplemental new drug application seeking this approval today.
Read More
Immune Approaches Hold Great Promise in Myeloma, Expert Says
August 27th 2018In an interview with <em>Targeted Oncology </em>during the2nd Annual Live Medical Crossfire: Hematologic Malignancies meeting, Alexander M. Lesokhin, MD, assistant attending physician in the Department of Medicine and Myeloma Service at Memorial Sloan Kettering Cancer Center, discussed the current treatment landscape of multiple myeloma and where he predicts the field will be in the next decade. He also shared his thoughts on the current research in CAR T-cell therapy.
Read More
Elotuzumab Triplet Granted Priority Review by FDA for Myeloma
August 23rd 2018A supplemental biologics license application for elotuzumab<em> </em>has been granted a priority review by the FDA for use in combination with pomalidomide and low-dose dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.<br />
Read More
FDA New Drug Application Completed for Selinexor in Multiple Myeloma
August 9th 2018Karyopharm Therapeutics has announced that a rolling submission of an FDA new drug application has been completed for selinexor as a treatment for patients with penta-refractory multiple myeloma, based on results from part 2 of the phase IIb STORM trial.
Read More
CAR-BCMA T Cells Show Promising Activity in Relapsed/Refractory Multiple Myeloma
August 2nd 2018Treatment with chimeric antigen receptor B-cell maturation antigen T cells induced substantial antitumor activity in patients with heavily treated relapsed/refractory multiple myeloma, according to results from a first-in-human clinical trial.
Read More
Triplet Regimens With Pomalidomide in Patients With Multiple Myeloma
August 2nd 2018Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.
Watch
In an interview with <em>Targeted Oncology</em>, Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the results from the OPTIMISMM trial. He also shared his insight on the significance of these findings and what he expects to see in the future for this patient population.
Read More
Patients With Multiple Myeloma See Improved PFS With Maintenance Ixazomib
July 11th 2018In topline findings from the phase III TOURMALINE-MM3 study, maintenance treatment with the proteasome inhibitor ixazomib improved progression-free survival compared with placebo in adult patients with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.
Read More
Comparing Results for 3-Drug and 2-Drug Regimens in Relapsed/Refractory Myeloma
July 11th 2018Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone.
Watch
Addition of Elotuzumab Significantly Prolongs PFS in Heavily Pretreated Myeloma
July 9th 2018Elotuzumab (Empliciti) added to pomalidomide (Pomalyst) and dexamethasone reduced the risk of disease progression by 46% in patients with relapsed/refractory multiple myeloma compared with pomalidomide and dexamethasone alone, according to findings from the phase II ELOQUENT-3 trial presented at the 2018 EHA Congress.
Read More
Expert Highlights Recent Daratumumab Data in Myeloma
July 9th 2018In an analysis of patients with relapsed/refractory multiple myeloma enrolled on the phase Ib MMY1001 trial, daratumumab (Darzalex) was shown to be safe and effective when added to the backbone of carfilzomib (Kyprolis) and dexamethasone. These findings, which were presented during the 2018 ASCO Annual Meeting, signaled promising efficacy in patients who are refractory to lenalidomide (Revlimid), according to lead study author Ajai Chari, MD.
Read More
A Look Back at FDA News in June
July 2nd 2018The FDA approved several indications in the month of June, including venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), the combination of binimetinib (Mektovi) plus encorafenib (Braftovi) in melanoma, and bevacizumab (Avastin) in ovarian cancer. The FDA also accelerated approvals for pembrolizumab (Keytruda) in cervical cancer and in primary mediastinal large B-cell lymphoma, while also granting a priority review to glasdegib for acute myeloid leukemia.
Read More